유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

sandoz gmbh - natalizumabas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ir 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - krono liga - imunosupresantai - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia gali būti suteikiamas kaip monotherapy atveju netolerancija, kad metotreksato ar kai tolesnis gydymas metotreksatu netinka. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

septodont - artikaino hidrochloridas/adrenalinas - injekcinis tirpalas - 40 mg/5 µg/ml - articaine, combinations

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

septodont - artikaino hidrochloridas/adrenalinas - injekcinis tirpalas - 40 mg/10 µg/ml - articaine, combinations

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - sufentanilis - injekcinis ar infuzinis tirpalas - 5 µg/ml - sufentanil

리투아니아 - 리투아니아어 - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - sufentanilis - injekcinis ar infuzinis tirpalas - 50 µg/ml - sufentanil

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - rukuronio arba vekuronio sukeltos nervų ir raumenų blokados pasikeitimas. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.